Best Motor Neuron Disease Treatment Doctors in India

What Patients with Motor Neuron Disease Worry About Most

Motor neuron disease (also called amyotrophic lateral sclerosis) is the diagnosis families fear most. The questions are direct: how long, will breathing fail, will swallowing fail, and what can actually be done. The answers depend on the subtype, the bulbar versus limb onset, and access to a multidisciplinary clinic. Riluzole, edaravone, and (where available) tofersen for SOD1-positive disease slow progression. Non-invasive ventilation and gastrostomy feeding extend life and improve quality of life. The right team makes a real difference even in this disease.

How Motor Neuron Disease Is Diagnosed

Diagnosis uses the Gold Coast criteria: progressive upper and lower motor neuron signs in at least one body region with exclusion of mimics. Electromyography shows widespread denervation. Magnetic resonance imaging of the brain and spinal cord rules out structural causes. Blood tests cover thyroid, vitamin B12, paraproteins, HIV, and creatine kinase. Genetic testing for SOD1, C9orf72, FUS, and TARDBP is done where family history exists or where targeted therapy is being considered.

Treatment Options for Motor Neuron Disease in India

Disease-modifying drugs include riluzole (extends survival by around three months on average), edaravone (intravenous, slows functional decline in selected early-stage patients), and tofersen (intrathecal, for SOD1-positive disease). Multidisciplinary care includes a neurologist, respiratory physician for non-invasive ventilation, gastroenterologist for percutaneous endoscopic gastrostomy feeding, speech and language therapist, physiotherapist, occupational therapist, and palliative care team from early on. Non-invasive ventilation started at the right time extends survival by around twelve months and improves quality of life clearly. Centres at All India Institute of Medical Sciences, National Institute of Mental Health and Neurosciences, Christian Medical College, Fortis Memorial Research Institute, Medanta, and Apollo run dedicated motor neuron disease clinics with full multidisciplinary teams.

Recovery, Success Rates, and Follow-Up

Motor neuron disease is currently incurable. Median survival from symptom onset is around three years but ranges widely. Around ten percent of patients live more than ten years. Tofersen for SOD1-positive disease has shown clear neurofilament reduction and slowed progression in trials. Follow-up runs every three months with forced vital capacity, weight, swallowing assessment, and functional rating scale tracked at each visit.

How to Choose the Right Motor Neuron Disease Doctor

Choose a neurologist running a dedicated multidisciplinary motor neuron disease clinic with respiratory medicine, gastroenterology, speech and language therapy, physiotherapy, and palliative care under one roof. Ask about non-invasive ventilation initiation timing, percutaneous endoscopic gastrostomy protocols, access to riluzole and edaravone, and whether the clinic offers tofersen for SOD1-positive patients. A single-doctor approach without team support is the wrong fit.

International Patient Support

Motor neuron disease care in India costs significantly less than in Western countries with full access to riluzole, edaravone, non-invasive ventilation, and percutaneous endoscopic gastrostomy. Cancer Rounds arranges the medical visa invitation letter, accommodation, multilingual support in eleven plus languages, and a single case manager throughout. Patients travel from Nigeria, Bangladesh, Kenya, Ethiopia, Iraq, Oman, and the United Arab Emirates for multidisciplinary motor neuron disease care.

Frequently Asked Questions

How long do patients live?

Median survival from symptom onset is around three years. Bulbar-onset and respiratory-onset cases progress faster. Limb-onset and younger patients often live longer. Around ten percent live more than ten years.

Does motor neuron disease affect the mind?

Around fifteen percent develop frontotemporal dementia. Up to half show milder behavioural or executive changes on detailed testing. Personality and judgment can change before memory.

Is non-invasive ventilation worth it?

Yes. It improves sleep, quality of life, and survival by around twelve months on average when started at the right time, usually when forced vital capacity falls below fifty percent or symptoms appear. It is non-invasive and used at night first.

When is percutaneous endoscopic gastrostomy needed?

When swallowing becomes unsafe or weight loss exceeds ten percent. Earlier placement is safer than waiting until breathing has weakened. It improves nutrition and reduces choking, and does not stop eating by mouth if that is still possible.

Is the disease inherited?

Around ten percent of cases are familial. C9orf72 expansion, SOD1, FUS, and TARDBP are the main genes. Genetic counselling is offered when family history exists. Most cases are sporadic with no clear inheritance.

What is tofersen?

An intrathecal antisense oligonucleotide that lowers mutant SOD1 protein. It is approved for patients with SOD1-positive motor neuron disease. Trials show clear neurofilament reduction and slowed progression in this subgroup.